Drug Development Unit

Aim: To explore, generate, and validate new combinatorial pharmacotherapies aimed at improving different aspects of the metabolic syndrome.

  • Design, synthesize, and explore the metabolic benefits of novel peptide hormone and nuclear hormone combinations;
  • Assess the preclinical efficacy of new multi-agonists at the GLP-1, GIP, and glucagon receptors;
  • Explore new pathways that mimic the metabolic benefits of cold exposure and assess their druggability.